Recurrent Nasopharyngeal Carcinoma Clinical Trials

27 clinical trials for Recurrent Nasopharyngeal Carcinoma across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer — RECRUITING · PHASE2
• Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma — RECRUITING · NA
• PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients — RECRUITING · PHASE3
• Proton Therapy for Recurrent Nasopharyngeal Carcinoma — RECRUITING · NA
• Adjuvant vs Surgery Only in Early-stage Recurrent NPC — RECRUITING · PHASE3
• Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC — RECRUITING · PHASE3
• Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma — RECRUITING · PHASE3
• Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer — SUSPENDED · PHASE2
• Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients — NOT_YET_RECRUITING · PHASE1
• Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer — TERMINATED · PHASE3
• Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma — NOT_YET_RECRUITING
• Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma — OTHER · PHASE2
• Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure — OTHER · PHASE2
• Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. — OTHER · PHASE2
• A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma — OTHER · NA
• Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC — OTHER · PHASE2
• Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma — OTHER · PHASE2
• Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT — NOT_YET_RECRUITING · PHASE3
• A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma — OTHER · PHASE2
• Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer — WITHDRAWN · PHASE2
• Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy — OTHER
• Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) — COMPLETED · PHASE2
• Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma — OTHER · PHASE1
• Nimotuzumab for Recurrent Nasopharyngeal Carcinoma — OTHER · PHASE2
• A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC. — OTHER · PHASE2
• MK-2206 in Recurrent Nasopharyngeal Carcinoma — COMPLETED · PHASE2

Refine this search